| Category | Models | Doses | Biological activities | Ref. |
| Anti-inflammation | UC mice | 25, 50, and 100 mg/kg | TNFα↓, IL-1β↓, IL-12↓, PPARγ↑, NF-κB↓, ZO-1↑, occludin↑ | [3] | LPS-induced ALI rats | 10 and 20 mg/kg | PPARγ↑, NF-κB↓, COX-2↓, iNOS↓, ROS↓, lung edema↓ | [34] | A549 | 20 and 50 μmol/L | ICAM-1↓, NF-κB↓, p38↓, ERK1/2↓, SAPK/JNK↓ | [35] | LPS-induced MUECs | 12.5, 25, 50μg/mL | TNFα↓, IL-6↓, p-ERK↓, p-JNK↓, p-p38↓, NF-κB↓, MAPK↓ | [38] | LPS-induced MMECs | 12.5, 25, 50μg/mL | IL-1, TNFα↓, IL-6↓, p-p65↓, p-IκBα↓, p-ERK↓, p-p38↓, p-JNK↓ | [39] |
| Anti- microorganism | LPS-induced RAW 264.7 | 5, 10, and 20μM | Nrf-2/HO-1↑, NF-κB↓, iNOS↓, COX-2↓, PGE2↓, NO↓ | [4] | MT8148 | 10, 20, and 50μg/mL | Good penetration and bactericidal activity on MT8148 biofilm | [43] | Channel catfish | 2, 4, 8, and 16μg/mL | Inhibit hemolytic activity of supernatants from A. hydrophila culture | [44] |
| Anti-oxidation | SAM | 10 and 30 mg/kg | 4-HNE↓, iNOS↓, p-p38 MAPK↓, IL-1β, TNFα↓, IL-6↓ | [6] | 3T3-L1 | 5, 10, and 20μM | ROS↓, FAS↓,SREBP1↓, UCP1↑, Cd137↑, Prdm16↑, Cidea↑, Tbx1↑, PGC-1α↑, CPT1↑, ACSL1↑, SIRT1↑, PLIN↑ | [7] | SH-5Y5Y | 8, 16, and 32μM | ROS↓, JNK/mitochondrial caspases↓, PI3K/MEK/ERK↓, PI3K/Akt/FOXO1↓ | [49] |
| Anti-cancer | U87MG and LN229 | 20 and 40μM | Cyclin A↓, cyclin D1↓, CDK 2↓, CDK4↓, CDK6↓, p-PI3K↓, p-Akt↓, p-p38↓, p-JNK↓, Ki67↓, p-ERK↑ | [11] | U373 | 10, 20, and 40μM | Arrest at G0/G1 phase, cyclin D1↓, cyclin A↓, CDK2↓, p21/Cip1↑ | [50] | U373 | 100μM | p27/Kip1↑, ↑phosphorylation of cSrc, ERK, p38, and Akt. | [51] | CCA | 20 and 40μM | Ki67↓, PCNA↓, MMP-2↓, MMP-7↓, MMP-9↓, CyclinD1↓, p-IκBα↓, p-p65↓ | [52] | Mice bladder cancer | 10 mg/kg/d | Myostatin↓, activin A↓, p-Akt↑, p-FOXO3↑, IGF-1↑, p-mTOR↑, p-p70S6K↑, p-4EBP-1↑ | [53] | HUVECs | 0.1, 0.5, and 1μM | Inhibit VEGF-stimulated proliferation, chemotactic motility, tube formation, and vessel sprouting, MEK/ERK↓, PI3K/Akt↓ | [54] |
| Neuroprotection | Scop-induced mice | 15, 25, and 35 mg/kg | AChE↑, total SOD↑, NOS↑, MDA↑ | [55] | CORT-induced rats | 50 and 100 mg/kg | FST↑, TST↑, BDNF↑, 5-HT↑, NE↑ | [56] | I/R mice | 1.4, 7.0, and 35 μg/kg | Decrease cerebral infarct volume, brain water content, and the exudation of Evans blue | [57] |
| Cardiovascular protection | SHR and HUVECs | 100 mg/kg/d and 10μM | Restore insulin-mediated Akt, eNOS, and aorta vasolidation, PPARγ↑, TRB3↓ | [15] | VSMCs | 5, 10, 20, and 30μM | Arrest at G0/G1, cyclinD1↓, cyclinE↓, CDK2↓, CDK4↓, p-ERK1/2↓, NF-κB↓ | [16] | HAECs | 5μM | JNK/p38 phosphorylation↓, HuR translocation↓, NF-κB↓, VCAM-1↓ | [58] |
| Metabolism regulation | RAW 264.7 | 20, 40, and 60μM | ADRP↓, lipolysis↓ | [17] | 3T3-L1 | 1 and 10μM | Enhances adipocytes differentiation and glucose uptake | [59] |
|
|